From RTTNews:

Pharming Group N.V. (PHAR) expects a 19% increase in total revenues to $245 million for 2023. RUCONEST revenues are predicted to rise by 10% to $227 million, while Joenja revenues are anticipated to reach $18 million. CEO Sijmen de Vries is optimistic about the 10% RUCONEST growth and the successful launch of Joenja for APDS in the U.S.

The company’s preliminary, unaudited cash and cash equivalents, along with restricted cash and marketable securities, are forecasted to total $215.0 million by the end of 2023. This financial stability bodes well for Pharming’s future prospects.

Pharming Group N.V.’s positive revenue projections and financial position indicate a strong business outlook for the company in the coming year. The successful launch of Joenja in the U.S., following FDA approval, has contributed to the company’s growth prospects for 2023. Investors and stakeholders can look forward to a promising year ahead for Pharming Group N.V.



Read more: Pharming Group Projects 2023 Total Revenues To Rise 19%